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Background: Transforming growth factor-β (TGF-β) plays an important role in regulating cellular functions, and
many studies have demonstrated important roles for TGF-β in various cancers. Single nucleotide polymorphisms
(SNPs) of TGF-β may influence lung carcinogenesis. The aim of this study was to test whether TGF-β1 C509T and
TGF-β receptor II (TGFBR2) G-875A polymorphisms were associated with lung adenocarcinoma in nonsmoking females.
Methods: A hospital-based case–control study was performed in Chinese nonsmoking females. Genotyping was
performed using TaqMan SNP genotyping assay, and demographic data and environmental exposure were
collected by trained interviewers after informed consents were obtained.
Results: A total of 272 (95.4%) cases and 313 (99.4%) controls were successfully genotyped, and the results
showed that the polymorphic allele frequencies of C509T and G875A were similar among lung adenocarcinoma
patients and controls (P=0.589 and 0.643, respectively). However, when the data were stratified for cooking oil
fume exposure, the TT genotype of the TGFB1 C509T polymorphism showed a significantly decreased risk for lung
adenocarcinoma compared with the CC genotype (adjusted OR=0.362, 95% CI=0.149–0.878, P=0.025).
Conclusions: TGF-β1 gene C509T polymorphism might be associated with decreased risk of lung
adenocarcinoma in Chinese females exposed to cooking oil fumes, but no association was observed TGFBR2 gene
G875A polymorphism.
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Lung cancer is one of the leading causes of cancer
related death in males and females [1]. Smoking is a
major risk factor in lung cancer development, and is
responsible for approximately 80% of all lung cancers
[2]. However, smoking alone cannot fully explain the
epidemiologic characteristics of lung cancer. Epide-
miological evidence has shown that only 20% smokers
develop lung cancer [3]. In addition, unlike smokers
common with squamous cell carcinomas, nonsmokers* Correspondence: bszhou@mail.cmu.edu.cn
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reproduction in any medium, provided the orespecially females were more likely to have adenocar-
cinoma [4]. Furthermore, the incidence and death rate
of lung cancer is now declining in men, while continuing
to increase in women. Thus, for the nonsmoking female
population, it is more important to study the impact
factors of lung adenocarcinoma.
Transforming growth factor-β (TGF-β) proteins repre-
sent an important family of cytokines that play an im-
portant role in regulating cellular functions such as cell
proliferation, differentiation, apoptosis, adhesion, inva-
sion and immune response [5-8]. Among the three TGF-β
isoforms expressed in mammals, including TGF-β1, TGF-
β2 and TGF-β3, TGF-β1 is the most commonly expressed
and abundant form in carcinogenesis [6]. TGF-β1 exerts
its effects by binding to TGF-β receptor II (TGFBR2) andis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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(TGFBR1) and downstream signaling [6,8]. Accumulating
evidence has demonstrated that TGF-β signaling plays a
dual role in carcinogenesis. TGF-β acts as a tumor
suppressor by inhibiting cell proliferation or promoting
cell differentiation and apoptosis in the early stage of
cancer, and as a tumor promoter by promoting tumor cell
invasion, dissemination and immune evasion in advanced
stages [5-8].
Several genetic variants in TGF-β1 and TGF-β2 genes
and receptors have been identified. The most studied
TGF-β1 genetic variant is the C509T polymorphism,
which was reported to increase the plasma level of TGF-
β1 by influencing its transcriptional activation [9]. Re-
cent studies have identified a relationship between this
polymorphism and the risk of cancer in prostate cancer
[10], esophageal cancer [11], breast cancer [12], gastric
cancer [13] and lung cancer [14,15]. However, in lung
cancer-focused studies, the results were inconsistent.
The common G875A polymorphism in the promoter re-
gion of TGFBR2 is also associated with transcriptional
activation of the gene [16]. To the best of our know-
ledge, there has been no report on the TGFBR2 G875A
polymorphism in lung adenocarcinoma.
Our previous study showed that cooking oil fume
exposure was a risk factor for lung adenocarcinoma
in Chinese nonsmoking females [17,18]. Furthermore,
cooking oil fume increased TGF-β1 secretion in lung
epithelial cells [19]. Therefore, we speculated that cooking
oil fume exposure may show an interaction with TGF-β1
in lung adenocarcinoma development. To test whether
the two polymorphisms in TGF-β1 and TGFBR2 were
associated with lung adenocarcinoma, a hospital-based
case–control study was performed in Chinese nonsmoking
females.
Methods
Study subjects and data collection
Cases and controls for this study have been described pre-
viously [17]. Briefly, we identified newly diagnosed non-
smoking female patients with histologically confirmed
lung adenocarcinoma from January 2002 to November
2007. Controls were selected from cancer-free female
patients with other lung diseases such as bronchitis,
pneumonias, fibrosis, sarcoidosis, and chronic obstructive
pulmonary disease. Controls were frequency matched to
cases on age (±5 years) and none were smokers. All sub-
jects were all unrelated Han Chinese. This investigation
was approved by the Institutional Review Board of China
Medical University. After informed consent was obtained
from each, cases and controls were interviewed in person
to collect demographic data and environmental exposure
information by trained interviewers, including demo-
graphic characteristics, passive smoking, cooking oil fumeexposure, fuel smoke exposure, family history of cancer,
occupational exposure and dietary habits. Individuals who
had smoked less than 100 cigarettes in their lifetime were
defined as nonsmokers. Participants who engaged in frying
or deep-frying in the kitchen more than two times each
week with reported eye or throat irritation were defined
with cooking oil exposure.
DNA isolation and genotyping
Genomic DNA was extracted from peripheral blood
using Proteinase K digestion and standard phenol-
chloroform methods. Genotyping was performed on the
Applied Bio-systems 7500 FAST Real-Time PCR System
(Foster City, CA, USA) using TaqMan single nucleotide
polymorphism (SNP) genotyping assay in a 10 μL total
reaction volume containing 5 μL 2× TaqMan Genotyp-
ing Master mix (Affymetrix Inc., Cleveland, Ohio, USA),
0.5 μL primers and probes (Applied Biosystems, assay
ID: C_8708473_10 and C_27491740_10) and 2 μL DNA
(15–25 ng/μL). After an initial denaturation at 95°C for
10 min, DNA was amplified by 47 cycles of 92°C for 30 s,
and 62°C for 1 min. Ten percent of all samples were ran-
domly selected and genotyped again for quality control.
Statistical analysis
Statistical analyses were performed using SPSS version
16.0 software (SPSS Inc., Chicago, IL). A value of P < 0.05
was considered statistically significant. Deviations from
the Hardy–Weinberg equilibrium for each SNP were
assessed using the Pearson χ2 test. The characteristics of
the patients with lung adenocarcinoma and the controls
were compared using Pearson χ2 test. The odds ratio
(OR) and its 95% confidence interval (CI) with adjust-
ment for age were obtained by logistic regression
method to determine the correlation between the two
polymorphisms, exposure information and the risk of
lung adenocarcinoma.
Results
Genomic DNA samples were extracted from 285 lung
adenocarcinoma cases and 315 cancer-free controls. A
total of 63 samples (31 cases and 32 controls) were
randomly selected for genotyping replication, and the
concordance rate was 100%. A final 272 cases and 313
controls were successfully genotyped and included for
further analyses. The demographic variables and envir-
onmental risk factors of the patients are listed in the
Table 1. All cases were lung adenocarcinoma patients
and females. There were no significant differences be-
tween the cases and controls in the distribution of age,
income, education, family history of cancer, passive
smoking and fuel smoke exposure. However, more cook-
ing oil fume exposure was reported in the cases group
(crude-OR=1.554, 95% CI=1.092–2.221, P=0.013).
Table 1 Selected variable in cases and controls
Variable Cases n (%) Controls n (%) P
Sample size 272 313
Age (years) 54.0±12.1 54.2±9.1 0.825
Income (yuan/mouth) 622.4±377.2 561.0±388.1 0.073
Education 0.945
Never 24 27
Elementary school 129 156
Junior school 79 85
Senior school and upwards 40 45
Family history of cancer 35 33
Passive smoking 161(59.2%) 178(56.9%) 0.570
Fuel smoke exposure 78(28.7%) 85(27.2%) 0.683
Cooking oil fume exposure 98(36.0%) 83(26.5%) 0.013
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TGF-β1 C509T and TGFBR2 G875A polymorphisms of
the cases and controls are shown in Table 2. The geno-
type distributions of both polymorphisms among the
controls were in Hardy–Weinberg equilibrium (P=0.528
and 0.361 for TGF-β1 C509T and TGFBR2 G875A, re-
spectively). No differences of genotypes for TGF-β1
C509T and TGFBR2 G875A between the cases and the
controls were detected (P=0.589 and 0.643, respectively)
or polymorphic allele frequencies (P=0.451 and 0.731,
respectively). However, when we performed the combinedTable 2 TGFB1 C-509T and TGFBR2 G-875A polymorphisms
and lung adenocarcinoma risk
Polymorphism Cases Controls ORadg 95% CI P
TGF-β1 C-509T
CC 78(28.7) 79(25.2) 1.0
CT 138(50.7) 162(51.8) 0.847 0.574-1.249 0.402
TT 56(20.6) 72(23.0) 0.768 0.480-1.228 0.270
CT/TT 194(71.3) 234(74.8) 0.822 0.569-1.188 0.298
C 294(54.0) 320(51.1) 1.0
T 250(46.0) 306(48.9) 0.878 0.697-1.106 0.270
TGFBR2 G-875A
GG 182(66.9) 202(64.5) 1.0
GA 80(29.4) 102(32.6) 0.865 0.605-1.237 0.427
AA 10(3.7) 9(2.9) 1.223 0.486-3.078 0.669
GA/AA 90(33.1) 111(35.5) 0.895 0.634-1.263 0.528
G 444(81.6) 506(80.8) 1.0
A 100(18.4) 120(19.2) 0.946 0.704-1.271 0.711
Combined analysis
0 Variant locus 54(19.9) 42(13.4) 1.0
1Variant locus 152(55.9) 197(62.9) 0.591 0.374-0.935 0.025
2 Variant locus 66(24.3) 74(23.6) 0.675 0.399-1.141 0.142
Abbreviation: ORadg age-adjusted odds ratio, CI confidence interval.analyses according to the number of variant loci for
these two SNPs (Table 2), those with one variant locus
had a decreased risk of lung adenocarcinoma. However,
this was not the case for carriers of two variant loci
(age-adjusted OR=0.591, 95% CI=0.374–0.935, P=0.025
for subjects carrying one variant locus; age-adjusted
OR=0.675, 95% CI=0.399–1.141, P=0.142 for subjects
carrying two variant loci).
In analysis stratified by cooking oil fume exposure, no
association was found between the TGF-β1 C509T poly-
morphism and the risk of lung adenocarcinoma in sub-
jects without exposure to cooking oil fumes (Table 3).
However, individuals exposed to cooking oil fumes with
TT genotype were at a significantly decreased risk of
lung adenocarcinoma compared with those with the CC
genotype (age-adjusted OR=0.362, 95% CI=0.149–0.878,
P=0.025) and in a dose–response manner (χ2=4.558,
P=0.033). Regarding the TGFBR2 G875A polymorphism,
no difference of genotype distribution between the two
groups was detected. In stratified analyses by fuel smoke
exposure and passive smoking status, as shown in Table 4
and Table 5, a nonsignificant association between the two
polymorphisms and lung adenocarcinoma was observed.
To evaluate the interaction of genetic polymorphism with
cooking oil fume exposure in lung adenocarcinoma, a lo-
gistic regression was performed; the crude OR and age-
adjusted OR value for the TT gene type with cooking oil
fume exposure were 0.331 (95% CI=0.116–0.942, P=0.038)
and 0.343 (95% CI=0.12–0.976, P=0.045), respectively
(data not shown). The P values for the interaction of TGF-
β1 and TGFBR2 with cooking oil fume exposure were
0.046 and 0.005, respectively.
For multiple comparisons, a Bonferroni correction was
performed. We genotyped 11 SNPs on these subjects, in-
volving 106 subsequent analyses in a total of five studies,
including four previously published studies [17,18,20,21]
and the current study. The adjusted statistically signifi-
cant level was 4.72 × 10−4, and therefore all the associa-
tions between polymorphisms and lung adenocarcinoma
were not statistically significant in the study.
Discussion
Lung cancer is currently the most common malignancy
in the world, and adenocarcinoma is most common in
females, especially in those who have never smoked. To
explore mechanisms involved in lung adenocarcinoma, we
investigated the influence of the TGF-β1 and TGFBR2
polymorphisms on the risk of lung adenocarcinoma in a
population-based case–control study. The TGF-β1 C509T
polymorphism was significantly associated with the risk of
lung adenocarcinoma in individuals exposed to cooking
oil fumes, and protective effects were observed in a
dose–response manner. This finding suggests that the
TGF-β1 C509T polymorphism could be used as genetic
Table 3 TGF-β1 C-509T and TGFBR2 G-875A polymorphisms and lung adenocarcinoma risk, stratified by cooking oil
fume exposure
Polymorphism Exposure to cooking oil fume Non exposure to cooking oil fume Pinteraction
Cases Controls ORadg 95% CI P Cases Controls ORadg 95% CI P
TGF-β1 C-509T 0.046
CC 31 20 1.0 47 59 1.0
CT 54 40 0.887 0.441-1.784 0.737 84 122 0.841 0.523-1.354 0.477
TT 13 23 0.362 0.149-0.878 0.025 43 49 1.065 0.606-1.870 0.827
CT/TT 67 63 0.693 0.358-1.342 0.277 127 171 0.906 0.578-1.420 0.666
TGFBR2 G-875A 0.005
GG 59 60 1.0 123 142 1.0
GA 34 23 1.451 0.761-2.766 0.258 46 79 0.674 0.435-1.047 0.079
AA 5 0 5 9 0.629 0.205-1.929 0.417
GA/AA 39 23 1.664 0.883-3.136 0.115 51 88 0.670 0.439-1.022 0.063
Abbreviation: ORadg age-adjusted odds ratio, CI confidence interval.
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vival rate of lung cancer patients was only 16%, but the
survival rate of clinical stage I could reach 59% [22].
This indicates that early diagnosis may increase survival
and improve the quality of life for lung cancer patients.
In the current study, the frequencies of the C509T and
G875A alleles among the healthy controls were 0.489
and 0.192, respectively, similar to previous studies in a
Chinese population [9,11,13,23]. Although the frequen-
cies of CT and TT homozygotes among lung adenocar-
cinoma patients were lower than those in the control
group (50.7% vs. 51.8% in CT, 20.6% vs. 23.0% in TT,
respectively), no significant association between the
TGF-β1 C509T polymorphism and the risk of lung
cancer was found. This result was different from the
study of Kang et al. [14], but similar to the findings of
Park et al. [15]. Several studies showed that TGF-β1
C509T polymorphisms are associated with TGF-β1Table 4 TGF-β1 C-509T and TGFBR2 G-875A polymorphisms a
exposure
Polymorphism Exposure to fuel smoke
Cases Controls ORadg 95% CI P
TGF-β1 C-509T
CC 21 17 1.0
CT 43 47 0.706 0.325-1.533 0.378
TT 14 21 0.501 0.195-1.289 0.152
CT/TT 57 68 0.642 0.305-1.353 0.244
TGFBR2 G-875A
GG 61 57 1.0
GA 15 24 0.594 0.280-1.257 0.173
AA 2 4 0.465 0.082-2.648 0.388
GA/AA 17 28 0.574 0.282-1.167 0.125
Abbreviation: ORadg age-adjusted odds ratio, CI confidence interval.production [9,14,24-26]. Grainger et al. [24] reported
that the variant T allele at C509T was associated with
higher plasma levels, and the TT homozygote was asso-
ciated with highest plasma levels. Luedecking et al. [26]
reported that the variant T allele was associated with in-
creased transcriptional activity. However, identical con-
clusions were reported by Wang et al. [9] and Peng
et al. [23], who found that the C allele rather than T al-
lele was associated with higher plasma levels and tran-
scriptional activity, respectively. Differences in ethnic
background and genetic heterogeneity in different can-
cers may be the main reason for these different results.
TGFBR2 is a key receptor in regulating the TGF-β sig-
naling pathway by binding to TGF-β and activating
TGFBR1, so mutations in TGFBR2 may inactivate or ac-
tivate the TGF-β signaling pathway [5,6]. To date, many
mutations in the TGFBR2 promoter have been reported
[27,28] that may contribute to reduced receptornd lung adenocarcinoma risk, stratified by fuel smoke
Non exposure to fuel smoke Pinteraction
Cases Controls ORadg 95% CI P
0.685
57 62 1.0
95 115 0.886 0.564-1.394 0.601
42 51 0.883 0.512-1.523 0.601
137 166 0.885 0.578-1.356 0.576
0.922
121 145 1.0
65 78 0.987 0.655-1.488 0.951
8 5 1.901 0.606-5.963 0.271
73 83 1.043 0.700-1.553 0.837
Table 5 TGF-β1 C-509T and TGFBR2 G-875A polymorphisms and lung adenocarcinoma risk, stratified by passive
smoking
Polymorphism Exposure to passive smoking Non exposure to passive smoking Pinteraction
Cases Controls ORadg 95% CI P Cases Controls ORadg 95% CI P
TGF-β1 C-509T 0.648
CC 21 17 1.0 57 62 1.0
CT 43 47 0.706 0.325-1.533 0.378 95 115 0.886 0.564-1.394 0.601
TT 14 21 0.501 0.195-1.289 0.152 42 51 0.883 0.512-1.523 0.601
CT/TT 57 68 0.642 0.305-1.353 0.244 137 166 0.885 0.578-1.356 0.576
TGFBR2 G-875A 0.213
GG 61 57 1.0 121 145 1.0
GA 15 24 0.594 0.280-1.257 0.173 65 78 0.987 0.655-1.488 0.951
AA 2 4 0.465 0.082-2.648 0.388 8 5 1.901 0.606-5.963 0.271
GA/AA 17 28 0.574 0.282-1.167 0.125 73 83 1.043 0.700-1.553 0.837
Abbreviation: ORadg age-adjusted odds ratio, CI confidence interval.
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ism is the only one in which minimum allele frequency
was less than 0.05 in the promoter region of TGFBR2
[16], and this polymorphism was reported as associated
with transcription activities of the gene [16]. To the best
of our knowledge, this is the first study that focused on
the relationship between TGFBR2 G875A polymorphism
and lung adenocarcinoma risk. However, no association
was found. Similar studies in other cancers such as gas-
tric cancer [13] and esophageal squamous cell carcinoma
[11] in Chinese populations reported different results,
probably because of genetic heterogeneity in the patho-
genesis of different cancers.
A previously published genome-wide association study
(GWAS) on the risk of developing lung cancer among
women in Asia observed no evidence of association for
TGF-β1 and TGFBR2 [29]. Our results are consistent
with the GWAS findings. Additionally, in our analysis
stratified by cooking oil fume exposure, a significant
association between the TGF-β1 C509T polymorphism
and the risk of lung adenocarcinoma in subjects with
cooking oil fume exposure was found. The published
GWAS has stronger evidence and extrapolation, and the
present study could provide some clues for lung cancer
in the population living in the northeastern part of
China. Some in vitro results support the results of our
study. Previous studies have shown that exposure to
cooking oil fume condensates could inhibit cell growth,
increase TGF-β1 secretion and induce oxidative stress in
human lung epithelial cells [19], suggesting that TGF-β1
may play a role in the adverse health effects of oil fumes.
However, the exact molecular mechanisms are far from
understood. Reactive oxygen species can lead to in-
creased TGF-β1 release in human lung epithelial cells
[30], and Leonarduzzi et al. [31] reported that 4-hydroxy
2,3-nonenal, a major aldehyde end product of lipidperoxidation, can also induce TGF-β1 secretion in mac-
rophages. This indicates that TGF-β1 may play an im-
portant role in oxidative stress induced by cooking oil
fumes. In addition, benzo[a]pyrene (B[a]P), a product of
heated rapeseed oil, has been also demonstrated to
increase TGF-β1 mRNA levels [32]. B[a]P can lead to
cell carcinogenesis by causing DNA damage [33], there-
fore we speculate that TGF-β1 might act as an protector
by regulating cell proliferation and apoptosis.
This study includes several limitations. First, the sample
size might not be large enough to detect the low
penetrance effect of the genes, especially for stratified
analysis. However, we used a trend χ2 test to explore the
dose–response manner of lung adenocarcinoma risk
and TGF-β1 C509T polymorphism in nonsmoking
female exposure to cooking oil fumes, and the power of
this result is 0.957 (data not shown). Second, the rate of
fuel smoke exposure is 37.2%, which is higher than that
of other regions of China, and we did not find any asso-
ciation between fuel smoke and lung adenocarcinoma.
We matched the controls to the cases on age and sex,
and age-adjusted ORs were calculated by logistic regres-
sion to decrease potential confounding bias caused by
age. Finally, hospital-based studies are likely to include
some selection bias and information bias. The exposure
assessment of cooking oil fume and fuel smoke was
performed by subjective reports, which has limited
accuracy. Further study is needed to assess these expo-
sures using controlled measurements and instruments.
Conclusions
Our study demonstrates that the variant genotypes in
the promoter of TGF-β1 might decrease the risk of lung
adenocarcinoma in females exposed to cooking oil fumes
(TT vs. CC: OR=0.362, P=0.025), but no effect was ob-
served with the TGFBR2 G875A polymorphism. However,
Ren et al. BMC Medical Genetics  (2015) 16:22 Page 6 of 6because genetic polymorphisms often vary in different
ethnic groups, these findings need to be confirmed in
larger groups. Further studies also need to clarify the
exact molecular mechanisms of interaction between
cooking oil fumes and TGF-β1.
Abbreviations
SNPs: Single nucleotide polymorphisms; TGFB1: Transforming growth
factor-β1; TGFBR2: Transforming growth factor receptorII; OR: Odds ratio;
CI: Confidence interval; B[a]P: Benzo[a]pyrene.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
YR designed the study, performed the data analysis and drafted the
manuscript. ZY, XL and WW performed blood samples and information
collection. KL and YW managed the experiment. PG assisted with results
interpretation and assisted with the writing. BZ provided administrative
direction, assisted with results interpretation, assisted with the writing, and
secured financial support for the study. All authors read and approved the
final manuscript.
Acknowledgements
The authors are most grateful to all the participants in the present study.
This study was supported by grant no.81272293 from National Natural
Science Foundation of China.
Received: 4 March 2013 Accepted: 27 March 2015
References
1. Jemal A, Bray F, Center MM. Global Cancer Statistics. Ca-Cancer J Clin.
2011;61:69–90.
2. Pesch B, Kendzia B, Gustavsson P, Jockel KH, Johnen G, Pohlabeln H, et al.
Cigarette smoking and lung cancer–relative risk estimates for the major
histological types from a pooled analysis of case–control studies. Int J
Cancer. 2012;131:1210–9.
3. Smyth JF. Cancer genetics and cell and molecular biology. Is this the way
forward? Chest. 1996;109:125S–9S.
4. Zang EA, Wynder EL. Differences in lung cancer risk between men and
women: examination of the evidence. J Natl Cancer Inst. 1996;88:183–92.
5. de Caestecker MP, Piek E, Roberts AB. Role of transforming growth factor-beta
signaling in cancer. J Natl Cancer Inst. 2000;92:1388–402.
6. Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression
and cancer progression. Nat Genet. 2001;29:117–29.
7. Gordon KJ, Blobe GC. Role of transforming growth factor-beta superfamily
signaling pathways in human disease. Biochimica Et Biophysica Acta-Mol
Basis Dis. 2008;1782:197–228.
8. Massague J. TGFbeta in Cancer. Cell. 2008;134:215–30.
9. Wang H, Zhao YP, Gao CF, Ji Q, Gressner AM, Yang ZX, et al. Transforming
growth factor beta 1 gene variants increase transcription and are associated
with liver cirrhosis in Chinese. Cytokine. 2008;43:20–5.
10. Ewart-Toland A, Chan JM, Yuan JW, Balmain A, Ma J. A gain of function
TGFB1 polymorphism may be associated with late stage prostate cancer.
Cancer Epidemiol Biomark Prev. 2004;13:759–64.
11. Jin G, Deng Y, Miao R, Hu Z, Zhou Y, Tan Y, et al. TGFB1 and TGFBR2
functional polymorphisms and risk of esophageal squamous cell carcinoma:
a case–control analysis in a Chinese population. J Cancer Res Clin Oncol.
2008;134:345–51.
12. Shin AS, Shu XO, Cai QY, Gao YT, Zheng W. Genetic polymorphisms of the
transforming growth factor-beta 1 gene and breast cancer risk: A possible
dual role at different cancer stages. Cancer Epidemiol Biomark Prev.
2005;14:1567–70.
13. Jin G, Wang L, Chen W, Hu Z, Zhou Y, Tan Y, et al. Variant alleles of TGFB1
and TGFBR2 are associated with a decreased risk of gastric cancer in a
Chinese population. Int J Cancer. 2007;120:1330–5.
14. Kang HG, Chae MH, Park JM, Kim EJ, Park JH, Kam S, et al. Polymorphisms in
TGF-beta1 gene and the risk of lung cancer. Lung Cancer. 2006;52:1–7.15. Park KH, Lo Han SG, Whang YM, Lee HJ, Yoo YD, Lee JW, et al. Single
nucleotide polymorphisms of the TGFB1 gene and lung cancer risk in a
Korean population. Cancer Genet Cytogenet. 2006;169:39–44.
16. Seijo ER, Song H, Lynch MA, Jennings R, Qong X, Lazaridis E, et al.
Identification of genetic alterations in the TGFbeta type II receptor gene
promoter. Mutat Res. 2001;483:19–26.
17. Yin Z, Su M, Li X, Li M, Ma R, He Q, et al. ERCC2, ERCC1 polymorphisms and
haplotypes, cooking oil fume and lung adenocarcinoma risk in Chinese
non-smoking females. J Exp Clin Cancer Res. 2009;28:153.
18. Li M, Yin Z, Guan P, Li X, Cui Z, Zhang J, et al. XRCC1 polymorphisms,
cooking oil fume and lung cancer in Chinese women nonsmokers. Lung
Cancer. 2008;62:145–51.
19. Tung YH, Ko JL, Liang YF, Yin L, Pu Y, Lin P. Cooking oil fume-induced
cytokine expression and oxidative stress in human lung epithelial cells.
Environ Res. 2001;87:47–54.
20. Shen L, Yin Z, Wu W, Ren Y, Li X, Zhou B. Single nucleotide polymorphism
in ATM gene, cooking oil fumes and lung adenocarcinoma susceptibility in
Chinese female non-smokers: a case–control study. PLoS One. 2014;9:e96911.
21. Yin Z, Cui Z, Ren Y, Zhang H, Yan Y, Zhao Y, et al. Genetic polymorphisms
of TERT and CLPTM1L, cooking oil fume exposure, and risk of lung cancer:
a case–control study in a Chinese non-smoking female population. Med
Oncol. 2014;31:114.
22. Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends,
and multiple primary cancer analyses from the Surveillance, Epidemiology,
and End Results (SEER) Program. Oncologist. 2007;12:20–37.
23. Qi P, Chen YM, Wang H, Fang M, Ji Q, Zhao YP, et al. −509C > T
polymorphism in the TGF-beta1 gene promoter, impact on the hepatocellular
carcinoma risk in Chinese patients with chronic hepatitis B virus infection.
Cancer Immunol Immunother. 2009;58:1433–40.
24. Grainger DJ, Heathcote K, Chiano M, Snieder H, Kemp PR, Metcalfe JC, et al.
Genetic control of the circulating concentration of transforming growth
factor type beta1. Hum Mol Genet. 1999;8:93–7.
25. Suthanthiran M, Li B, Song JO, Ding R, Sharma VK, Schwartz JE, et al.
Transforming growth factor-beta 1 hyperexpression in African-American
hypertensives: A novel mediator of hypertension and/or target organ
damage. Proc Natl Acad Sci U S A. 2000;97:3479–84.
26. Luedecking EK, DeKosky ST, Mehdi H, Ganguli M, Kamboh MI. Analysis of
genetic polymorphisms in the transforming growth factor-beta1 gene and
the risk of Alzheimer's disease. Hum Genet. 2000;106:565–9.
27. Munoz-Antonia T, Li X, Reiss M, Jackson R, Antonia S. A mutation in the
transforming growth factor beta type II receptor gene promoter associated
with loss of gene expression. Cancer Res. 1996;56:4831–5.
28. Hougaard S, Norgaard P, Abrahamsen N, Moses HL, Spang-Thomsen M,
Skovgaard Poulsen H. Inactivation of the transforming growth factor beta
type II receptor in human small cell lung cancer cell lines. Br J Cancer.
1999;79:1005–11.
29. Lan Q, Hsiung CA, Matsuo K, Hong YC, Seow A, Wang Z, et al. Genome-wide
association analysis identifies new lung cancer susceptibility loci in
never-smoking women in Asia. Nat Genet. 2012;44:1330–5.
30. Bellocq A, Azoulay E, Marullo S, Flahault A, Fouqueray B, Philippe C, et al.
Reactive oxygen and nitrogen intermediates increase transforming growth
factor-beta1 release from human epithelial alveolar cells through two
different mechanisms. Am J Respir Cell Mol Biol. 1999;21:128–36.
31. Leonarduzzi G, Scavazza A, Biasi F, Chiarpotto E, Camandola S, Vogel S, et al.
The lipid peroxidation end product 4-hydroxy-2,3-nonenal up-regulates
transforming growth factor beta1 expression in the macrophage lineage: a
link between oxidative injury and fibrosclerosis. FASEB J. 1997;11:851–7.
32. Zhang L, Shiverick KT. Benzo(a)pyrene, but not 2,3,7,8-tetrachlorodibenzo-p-
dioxin, alters cell proliferation and c-myc and growth factor expression in
human placental choriocarcinoma JEG-3 cells. Biochem Biophys Res
Commun. 1997;231:117–20.
33. Guengerich FP. Metabolic activation of carcinogens. Pharmacol Ther.
1992;54:17–61.
